Biochemical parameters of growth inhibition of human leukemia cells by antitumor anthracycline agents
- PMID: 287555
Biochemical parameters of growth inhibition of human leukemia cells by antitumor anthracycline agents
Abstract
Ten antitumor anthracycline derivatives used in this study inhibit growth of a human leukemia cell line over a range of potencies exceeding four orders of magnitude. The agents vary from each other at C-4 and C-13, with stereochemical differences at C-4' and substitutions at C-14 and N. Drug retention, DNA damage, and inhibition of DNA synthesia are parameters used to express potency of the agents in a mathematic model. Estimates of DNA damage are sufficient, however, to describe growth inhibition by a single agent (4-demethoxydaunorubicin). It may be possible now to attempt to extend the model to predict therapeutic responses to a number of anthracyclines, thereby enhancing the clinical utility of this important class of agents.
Similar articles
-
Quantitative models for growth inhibition of human leukemia cells by antitumor anthracycline derivatives.Cancer Res. 1979 Sep;39(9):3661-72. Cancer Res. 1979. PMID: 476691
-
The anthracycline antineoplastic drugs.N Engl J Med. 1981 Jul 16;305(3):139-53. doi: 10.1056/NEJM198107163050305. N Engl J Med. 1981. PMID: 7017406 Review. No abstract available.
-
DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.Cancer Res. 1989 Nov 1;49(21):5969-78. Cancer Res. 1989. PMID: 2551497
-
Experimental evaluation of anthracycline analogs.Cancer Treat Rep. 1979 May;63(5):835-44. Cancer Treat Rep. 1979. PMID: 455325
-
Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.Cancer Treat Rep. 1986 Jan;70(1):51-63. Cancer Treat Rep. 1986. PMID: 2935251 Review. No abstract available.
Cited by
-
Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro.Cancer Chemother Pharmacol. 1985;14(3):194-201. doi: 10.1007/BF00258115. Cancer Chemother Pharmacol. 1985. PMID: 3858013
-
Comparison of the intracellular pharmacokinetics of doxorubicin and 4'-epi-doxorubicin in patients with acute leukemia.Cancer Chemother Pharmacol. 1989;24(4):225-9. doi: 10.1007/BF00257622. Cancer Chemother Pharmacol. 1989. PMID: 2752502
-
Intracellular uptake and cytotoxic effect in vitro of doxorubicin and epirubicin in human leukemic and normal hematopoietic cells.Cancer Chemother Pharmacol. 1991;29(1):7-12. doi: 10.1007/BF00686328. Cancer Chemother Pharmacol. 1991. PMID: 1742852
-
Effect of pH and moderate hyperthermia on doxorubicin, epirubicin and aclacinomycin A cytotoxicity for Chinese hamster ovary cells.Cancer Chemother Pharmacol. 1993;33(2):144-8. doi: 10.1007/BF00685332. Cancer Chemother Pharmacol. 1993. PMID: 8261573
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous